Literature DB >> 32254027

Safety and efficacy of tranexamic acid with epinephrine for prevention of blood loss following surgery for trochanteric femoral fractures.

Xinxian Xu1, Linghui Xie2, Huachen Yu1, Yuezheng Hu1.   

Abstract

OBJECTIVE: This study aimed to determine whether the local administration of tranexamic acid (TXA) combined with diluted epinephrine (DEP) reduces blood loss and the need for transfusions compared with the administration of TXA alone following surgery for trochanteric femoral fractures.
METHODS: Hundred patients were enrolled in this study. In the target group (TXA/DEP group: n=50; 19 men and 31 women, mean age 72.5±11.1 years), the surgical sites were injected with 35 mL normal saline mixed with 3 g of TXA with 0.2 mg of DEP at a 1:200,000 dilution (TXA/DEP) immediately after musculoaponeurotic closure. In the control group (TXA group: n=50; 22 men and 28 women; mean age: 70.5±12.2 years), the surgical site was injected with 35 mL normal saline containing 3 g of TXA alone. The main outcome measures were postoperative hemoglobin (Hb) levels, hematocrit, drainage volume, and total blood loss (TBL); the secondary measures included transfusion requirements and perioperative complications.
RESULTS: The mean Hb levels among patients in theTXA/DEP group were significantly lower than among those in the TXA group, measured on postoperative day 1 at 101.0±14.1 g/L vs. 106.9±10.5 g/L and day 3 as 104.2±8.2 g/L vs. 108.5±9.1 g/L, respectively (p<0.05). Drainage volume from the surgical site and TBL measured on postoperative day 2 were also significantly reduced in the TXA/DEP group vs. the TXA group, measured at 71.4±26.0 mL vs. 82.5±24.6 mL and 343.6±148.0 mL vs. 419.6±165.4 mL, respectively (p<0.05). Furthermore, 11 patients (22%) from the TXA group and 15 (30%) from the TXA/DEP group received blood transfusions; the mean number of transfusion events (1.2±0.4 vs. 1.9±0.7) and the amount of blood transfused (1.7±0.5 Units vs. 2.9±1.0 Units) was also markedly reduced in the TXA/DEP group (p<0.05). Two cases in the TXA/DEP group and three in the TXA group were diagnosed with deep vein thrombosis, a difference that did not reach statistical significance (p>0.05).
CONCLUSION: Local administration of TXA with DEP reduced blood loss and limited the need for blood transfusions after surgery for trochanteric femoral fracture without increasing the risk of perioperative complications. Our study indicates that the local administration of TXA/DEP is safe and more effective than the administration of TXA alone in treating trochanteric femoral fractures. LEVEL OF EVIDENCE: Level III, Therapeutic study.

Entities:  

Year:  2020        PMID: 32254027      PMCID: PMC7286172          DOI: 10.5152/j.aott.2020.02.135

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  21 in total

Review 1.  Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials.

Authors:  Zhi-Jun Li; Xin Fu; Dan Xing; Hua-Feng Zhang; Jia-Cheng Zang; Xin-Long Ma
Journal:  Eur Spine J       Date:  2013-05-09       Impact factor: 3.134

2.  Topical Administration of Tranexamic Acid Plus Diluted-Epinephrine in Primary Total Knee Arthroplasty: A Randomized Double-Blinded Controlled Trial.

Authors:  Fuqiang Gao; Wei Sun; Wanshou Guo; Zirong Li; Weiguo Wang; Liming Cheng
Journal:  J Arthroplasty       Date:  2015-03-14       Impact factor: 4.757

3.  Risk factors for trochanteric and femoral neck fracture.

Authors:  A R Díaz; P Z Navas
Journal:  Rev Esp Cir Ortop Traumatol (Engl Ed)       Date:  2018-02-21

4.  Efficacy of Local Administration of Tranexamic Acid for Blood Salvage in Patients Undergoing Intertrochanteric Fracture Surgery.

Authors:  Athanasios Drakos; Vasilios Raoulis; Konstantinos Karatzios; Nikolaos Doxariotis; Vasilios Kontogeorgakos; Konstantinos Malizos; Sokratis E Varitimidis
Journal:  J Orthop Trauma       Date:  2016-08       Impact factor: 2.512

Review 5.  Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo.

Authors:  R von Känel; J E Dimsdale
Journal:  Eur J Haematol       Date:  2000-12       Impact factor: 2.997

6.  Epinephrine in irrigation fluid for visual clarity in arthroscopic shoulder surgery: a systematic review and meta-analysis.

Authors:  Liang-Tseng Kuo; Chi-Lung Chen; Pei-An Yu; Wei-Hsiu Hsu; Ching-Chi Chi; Jae-Chul Yoo
Journal:  Int Orthop       Date:  2018-06-22       Impact factor: 3.075

7.  Blood loss in trochanteric fractures: multivariate analysis comparing dynamic hip screw and Gamma nail.

Authors:  Mario Ronga; Daniele Bonzini; Marco Valoroso; Giuseppe La Barbera; Jacopo Tamini; Mario Cherubino; Paolo Cherubino
Journal:  Injury       Date:  2017-10       Impact factor: 2.586

8.  A randomized trial of the effect of low dose epinephrine infusion in addition to tranexamic acid on blood loss during total hip arthroplasty.

Authors:  Ø Jans; U Grevstad; H Mandøe; H Kehlet; P I Johansson
Journal:  Br J Anaesth       Date:  2016-01-27       Impact factor: 9.166

Review 9.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

10.  Tranexamic acid is effective in lower doses with infusion in total knee arthroplasty.

Authors:  Hande Gurbuz Aytuluk; Hasan Onur Yaka
Journal:  Acta Orthop Traumatol Turc       Date:  2019-01-09       Impact factor: 1.511

View more
  2 in total

1.  The efficacy and safety of intravenous tranexamic acid on blood loss during total ankle replacement: a retrospective study.

Authors:  Gang Tan; Li Wei Xie; Shi Jiu Yi; Yu Chen; Xi Liu; Hui Zhang
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

2.  Investigation of the Effects of Intra-articular Tranexamic Acid on Intact Cartilage Tissue and Cartilage Formation in Osteochondral Defects of the Rabbit Knee: An Experimental Study.

Authors:  Fevzi Bi Ri Si K; Serkan Bayram; Mehmet Çakmak; Evşen Apaydın; Ali Erşen
Journal:  Cureus       Date:  2021-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.